Latest Regulatory Filings News

Platinum Asia Investments Limited (PAI) shares have been suspended following Federal Court approval of a scheme exchanging all shares for units in the Platinum Asia Fund Complex ETF (PAXX). This marks a significant structural shift for PAI investors.

Sayona Mining’s merger with Piedmont Lithium faces further delay due to shareholder quorum shortfall, prompting an extension of its financing agreement with Resource Capital Fund VIII. The extension includes a potential AU$38 million capital injection through new options.

The Supreme Court of New South Wales has approved DP World Australia’s acquisition of Silk Logistics, paving the way for a $2.14 per share cash payout to Silk shareholders and imminent suspension of Silk shares on the ASX.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

Solis Minerals has voluntarily delisted from the TSX Venture Exchange to concentrate on its primary ASX listing, prompting changes to its ASX waivers and financial reporting calendar.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Findi Limited has appointed DAM Capital and Ambit as lead managers for the IPO of its Indian subsidiary, Transaction Solutions International, targeting a valuation near A$900 million and a 2026 listing.

Brookside Energy has expanded its SWISH Play acreage in Oklahoma's Anadarko Basin by adding a fifth Drilling Spacing Unit, increasing its high-impact drilling inventory by over a quarter. This move strengthens its development pipeline ahead of a planned NYSE listing.